Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Elena Del Alcázar-ViladomiuAnna López-FerrerÁlvaro Martínez DomenechRicardo Ruiz VillaverdeMar Llamas VelascoVicenç RocamoraMarc JuliàJaime NotarioLourdes Rodríguez Fernández-FreireAntonio Sahuquillo-TorralbaDavid VidalRaquel Rivera-DíazGregorio CarreteroAlmudena MateuPablo de la CuevaY José Manuel CarrascosaPublished in: Dermatologic therapy (2021)
The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value.